“In Q4, we expect our restored earnings power and strong operating margin expansion to continue, resulting in high-single-digit adjusted EPS growth in the back half of our fiscal year, consistent to the commitment that we have been sharing all year.”

In context

“in the range of 4.75 to 5%. For Q4, given the strong trajectory of our growth drivers and expected acceleration in the cardiovascular portfolio, we're comfortable with current street organic revenue growth consensus and expect to deliver our 10th quarter in a row of mid-single-digit revenue growth. Based on recent rates, FX would have an impact to fiscal ‘25 in the range of $275 million to $325 million, including $125 million to $175 million in the fourth quarter. On the bottom line, we continue to expect fiscal ‘25 non-GAAP diluted EPS in the range of $5.44 to $5.50 and are comfortable with current full-year street consensus. Based on recent rates, our EPS guide factors in a five-point impact from foreign currency, and we will have a significantly smaller impact than that in fiscal ‘26. In Q4, we expect our restored earnings power and strong operating margin expansion to continue, resulting in high-single-digit adjusted EPS growth in the back half of our fiscal year, consistent to the commitment that we have been sharing all year. Further details on our guidance can be found in the guidance slide in our presentation. Geoff, back to you. Geoff Martha: Thank you, Gary. And I want to thank you for stepping in as CFO over the last few quarters. I know you're going to help ensure a smooth transition as we welcome Terry, and I look forward to your continued contributions to Medtronic. Now, Terry will be joining us in a couple of weeks. And as I've heard from several of you in the investment community, it sounds like your checks are confirming what led us to hire him. He has a very strong reputation for his operational focus and ability to lead organizations to drive margin improvement, portfolio management, and earnings power to create shareholder value. Now before we go to analysts' questions, I'll share a few final tho”